<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378702</url>
  </required_header>
  <id_info>
    <org_study_id>viscum-1</org_study_id>
    <secondary_id>2007-002166-35</secondary_id>
    <nct_id>NCT01378702</nct_id>
  </id_info>
  <brief_title>Safety and Immunological Effects of Two Mistletoe Preparations in Healthy Volunteers</brief_title>
  <official_title>Safety and Immunological Effects of Iscucin Populi and Viscum Mali e Planta Tota in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to describe safety, tolerability and the course of
      parameters of the immune system during administration of different doses of two
      subcutaneously administered mistletoe preparations (Iscucin populi and Viscum Mali e planta
      tota) in healthy volunteers, compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>After 4 weeks treatment with each dose</time_frame>
    <description>Week 4 after baseline: evaluation of Iscucin populi strength F and Viscum Mali D3, respectively, compared to placebo. Week 8 after baseline: evaluation of Iscucin populi strength G and Viscum Mali D2, respectively, compared to placebo. Week 12 after baseline: evaluation of Iscucin populi strength H and Viscum mali 2%, respectively, compared to placebo. Week 16 after baseline: final follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>After 4 weeks treatment with each dose</time_frame>
    <description>see primary outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil counts</measure>
    <time_frame>After 4 weeks treatment with each dose</time_frame>
    <description>see primary outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Granulocyte counts</measure>
    <time_frame>After 4 weeks treatment with each dose</time_frame>
    <description>see primary outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte counts</measure>
    <time_frame>After 4 weeks treatment with each dose</time_frame>
    <description>see primary outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell counts</measure>
    <time_frame>After 4 weeks treatment with each dose</time_frame>
    <description>see primary outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General tolerability of the treatment(excellent, good, moderate or bad)</measure>
    <time_frame>After 4 weeks treatment with each dose</time_frame>
    <description>see primary outcome measure. Toleability will be indicated by the participants on a 4-point rating scale with the items &quot;excellent&quot;, &quot;good&quot;, &quot;moderate&quot; or &quot;bad&quot;, which will be coded by 1, 2, 3 or 4.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Iscucin populi strength F, G and H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 ampoule two times/week subcutaneously. Week 1-4: strength F. Week 5-8: strength G. Week 9-12: strength H.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Viscum Mali e planta tota D3, D2, 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 ampoule two times a week subcutaneously. Week 1-4: D3. Week 4-8: D2. Week 9-12: 2%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 ampoule two times a week subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mistletoe preparations</intervention_name>
    <description>1 ampoule (1ml) twice per week subcutaneously</description>
    <arm_group_label>Iscucin populi strength F, G and H</arm_group_label>
    <arm_group_label>Viscum Mali e planta tota D3, D2, 2%</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>1. Mistletoe from the poplar tree</other_name>
    <other_name>2. Mistletoe from the apple tree</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-45 years. Healthy volunteers

        Exclusion Criteria:

          -  Any disease except hay fever.

          -  Smoking.

          -  Drug abuse.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Huber, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univerity Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uni-zentrum-naturheilkunde.de</url>
    <description>Center for Complementary Medicine, University Hospital Freiburg</description>
  </link>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2011</study_first_posted>
  <last_update_submitted>June 20, 2011</last_update_submitted>
  <last_update_submitted_qc>June 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Roman Huber, Dr</name_title>
    <organization>University Hospital Freiburg</organization>
  </responsible_party>
  <keyword>Mistletoe</keyword>
  <keyword>Anthroposophical medicine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

